Whilst the alternate donor site (AD) event in NFATC4 has been identified as a poor prognostic indicator for overall survival in gastric cancer [67], its association with overall survival appears to be the opposite in pancreatic cancer [68]. Here, NFATC4 is linked to pancreatic neoplasm.